Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma
Otolaryngology–Head and Neck Surgery · 2026
DOI: 10.1002/ohn.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Takayoshi Hattori und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Melanoma, Head and Neck Neoplasms, Piperazines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Mucosal melanoma (MM) is an extremely aggressive malignant tumor in the head and neck region associated with a poor prognosis. In the present study, we conducted cell proliferation assay and western blotting using cell lines derived from MM and the immunohistochemical analysis of pathological MM tissues to identify novel therapeutic targets. Herein, we report on the potential of cyclin‐dependent kinase 4 (CDK4) inhibitors as molecular targeted therapies for MM. Study Design Retrospective cohort study and laboratory analysis.
Setting
A tertiary referral center.
Methods
MTT assay and western blotting were performed on the HMV‐II (RCB0777) and GAK (JCRB0180) cell lines, treated with the CDK4 inhibitors abemaciclib (LY2835219) and palbociclib (PD‐0332991). This retrospective cohort study included patients with head and neck MM; immunohistochemistry was performed on clinical specimens.
Results
Abemaciclib and palbociclib showed concentration‐dependent cytostatic effects on HMV‐II and GAK cells at 72 hours in the MTT assay. In western blotting, they exhibited concentration‐dependent inhibitory effects on phosphorylated RB1 in HMV‐II and GAK cells at 24 hours. Of 23 patients, 18 (78.3%) had positive results on CDK4 immunostaining. No clinicopathologic factors were significantly associated with CDK4 status.
Conclusion
Abemaciclib and palbociclib may suppress MM cell proliferation. The CDK4 signaling pathway is a potential target for molecular‐targeted therapies in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Genomic Oncology, Oral Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Medical Systems Engineering, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Medical Education Institute of Biomedical & Health Sciences, Center for Medical Education Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Takayoshi Hattori, Tsutomu Ueda, Akira Ishikawa, Yuichi Mine, Minoru Hattori, Takashi Ishino, Sachio Takeno
Zitieren
APA
Hattori, T., Fujii, M., Ueda, T., Ishikawa, A., Mine, Y., Xu, B., Suehiro, T., Hattori, M., Tahara, H., Sato, Y., Chikuie, N., Taruya, T., Hamamoto, T., Ishino, T., & Takeno, S. (2026). Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70137
Vancouver
Hattori T, Fujii M, Ueda T, Ishikawa A, Mine Y, Xu B, et al. Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70137
BibTeX
@article{Hattori2026,
author = {Hattori, Takayoshi and Fujii, Makiko and Ueda, Tsutomu and Ishikawa, Akira and Mine, Yuichi and Xu, Bingwen and Suehiro, Tomoya and Hattori, Minoru and Tahara, Hiroaki and Sato, Yuki and Chikuie, Nobuyuki and Taruya, Takayuki and Hamamoto, Takao and Ishino, Takashi and Takeno, Sachio},
title = {Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70137}
}
EUVIMED